Compare Automatic Data Processing Inc (ADP) vs Novavax Inc (NVAX) Price & Performance

ADP trades at $268.23, down 1.99% over the past day, with a bullish technical signal from moving averages and a consensus analyst price target of $280.50. The company reported strong earnings beats in recent quarters, with Q4 2026 EPS of $2.62 beating expectations, and maintains robust profitability with a net income margin of 20.11%. Recent news highlights dividend declarations and positive earnings momentum, though valuation ratios like a P/E of 24.78 suggest a premium.

The outlook for ADP is supported by consistent earnings growth and solid cash flow, but high valuation multiples and competitive pressures in payroll processing pose risks. Upside potential exists if the company meets Q3 2026 EPS expectations of $2.78, while macroeconomic labor market trends could impact performance. Analyst sentiment is mixed, with 63.89% holding, indicating cautious optimism amid elevated pricing.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.